Midgard Science

TRiCBIO

Nanjing, China tricbio.com

From their website, Nov 2026

Work here? Claim this listing

About

TRiCBIO provides human organoid-based research services for drug discovery, efficacy, safety, mechanism, immune-context, and custom model development. It works with biopharma, CRO, and research collaboration projects, with studies run from Nanjing and project support from Shanghai and Philadelphia.

Services

  • Organoid target discovery & functional genomics

    Discover genetic dependencies through organoid library screening and validate targets with tumor, microenvironment, and treatment-response readouts.

  • Target validation & mechanism studies

    Test candidate targets in human organoids through disease phenotypes, molecular changes, and treatment response.

  • Mechanism & biomarker studies

    Link tissue, functional, and molecular results to treatment response and prioritize biomarker candidates for validation.

  • Custom model development

    Develop model and assay plans for specialized tissues, rare diseases, or complex co-cultures based on available samples and endpoints.

  • Organoid efficacy screening

    Compare single agents and combinations in tumor PDOs and selected human organoid models to identify dose responses and differences across models.

  • Immuno-oncology

    Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures with tissue imaging and functional assays.

  • Antibody, multispecific & T-cell engager (TCE) studies

    Compare tumor-cell killing, immune activation, and cytokine changes for antibody, multispecific, and TCE candidates in human tumor organoids and immune co-cultures.

  • ADC research

    Combine target expression, spatial distribution, cytotoxicity, and bystander-effect readouts in organoid studies matched to ADC candidates.

  • Safety & toxicology

    Compare dose- and exposure-related responses in normal-tissue organoids using morphology, function, and injury markers to assess organ risk.

  • Multi-organ safety in human organoids

    Compare normal kidney, lung, and GI organoids with adjacent non-tumor liver or other models in coordinated exposure designs to rank organ risks.

  • Drug delivery & barrier permeability

    Assess barrier integrity, injury, and repair, then develop permeability or candidate-transport assays for the relevant tissue system.

  • Mechanism & biomarkers

    Link tissue, functional, and molecular results to treatment response and prioritize biomarker candidates for validation.

  • Human intestinal organoid IBD-like inflammation model

    Study IBD-like inflammation in human intestinal organoids through morphology, FITC-Dextran, IL-8, and image-based candidate readouts.

  • Tailored ADPKD organoid cyst-phenotype studies

    Develop cyst-phenotype and candidate-intervention studies for autosomal dominant polycystic kidney disease using hPSC-derived kidney organoids.

  • BBB co-culture & permeability methods

    Build HUVEC–astrocyte co-culture and ZO-1 junction imaging methods with permeability, candidate-response, and transport assays.

What to send
Tell us your study objective, candidate or sample, and the result that matters most. · Share the study objective and any available sample or candidate context.

Capabilities

Assays and studies
Antibodies · ADCs · Flow cytometry · Toxicology · Small molecules · Library screening · Functional genomics · Target validation · Mechanism studies · Morphology · Histology · Immunofluorescence
12 moreCytokine assays · Viability · Apoptosis · Gene expression/qPCR · Barrier permeability · Transport assays · Injury marker analysis · Genetic-library screening · Treatment-response studies · Functional assays · H&E · IHC
Scale and capacity
ALI · 96-well adaptable · 24-well · 96-well adaptable
Therapeutic areas
Oncology · Immuno-oncology · Kidney injury · Gastrointestinal disease · Inflammatory bowel disease · ADPKD · Blood-brain barrier · Head and neck cancer · Mesenchymal tumors · Drug discovery · Drug development · Safety
3 moreInflammation · Inherited kidney disease · Neurovascular-barrier research

Instruments and platforms

  • Flow cytometry
  • H&E
  • IHC
  • IF
  • Microscopy equipment

Modalities and species

Modalities
Small molecule · Antibody · Bispecific · ADC
Species and models
Human tumor organoids · Human kidney organoids · Normal lung organoids · Human intestinal organoids · Adjacent non-tumor liver organoids · H9 human embryonic stem cell (hESC)-derived kidney organoids · HUVEC–astrocyte co-culture · Patient-derived tumor organoids (PDO 1.0, PDO 2.0 / ALI) · IBD-like intestinal organoid model · ADPKD hPSC-derived kidney organoids · Human organoids · PDO 1.0
6 morePDO 2.0 · ALI tumor-immune organoids · Tumor PDOs · Normal-tissue organoids · Human intestinal organoid · hPSC-derived kidney organoids

Industries served

  • Biopharma
  • CRO
  • Biotech
  • Academic research

Company

Type
CRDMO
Quality
Model QC (morphology, markers and functional readouts) · batch QC (model and assay summary, model/batch QC, original images or data, and study report) · model quality assessed through morpholog · methods, results and data sources docume

Locations

Based in
Nanjing, China
Sites
Nanjing, China · Shanghai, China · Philadelphia, US
Serves
China, global, global clients

Contacts

Similar labs

Work here? Claim this listing